Sera Prognostics (SERA) Expected to Announce Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) will likely be announcing its Q4 2025 results after the market closes on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.0320 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 5:00 PM ET.

Sera Prognostics Stock Down 5.2%

Shares of Sera Prognostics stock opened at $1.83 on Wednesday. The company has a market cap of $70.64 million, a price-to-earnings ratio of -2.38 and a beta of 1.01. The company’s 50 day moving average is $2.80 and its 200 day moving average is $3.06. Sera Prognostics has a twelve month low of $1.37 and a twelve month high of $4.34.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SERA. Squarepoint Ops LLC grew its position in Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after purchasing an additional 7,643 shares during the period. Citadel Advisors LLC raised its position in shares of Sera Prognostics by 1.9% during the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock worth $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Lido Advisors LLC purchased a new position in shares of Sera Prognostics in the third quarter valued at approximately $68,000. Cetera Investment Advisers acquired a new position in Sera Prognostics in the 4th quarter valued at $74,000. Finally, Barclays PLC lifted its holdings in Sera Prognostics by 267.4% in the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock valued at $108,000 after purchasing an additional 26,726 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Jefferies Financial Group raised Sera Prognostics to a “strong-buy” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.